THIS INITIATIVE HAS BEEN SUPPORTED BY HELSINN THROUGH AN UNRESTRICTED EDUCATIONAL GRANT TO
MAGDALEN MEDICAL PUBLISHING LTD
Current treatment landscape for MDS and future developments
Clinical management of high-risk MDS patients and the potential utility of HDAC inhibitors
Ehab Atallah, MD, of the Medical College of Wisconsin, Milwaukee, WI, discusses the current treatment options for managing myelodysplastic syndrome (MDS), particularly in high-risk patients who could eventually develop acute myeloid leukemia (AML). Part of the challenge of managing MDS is establishing the prognosis and selecting a treatment plan from the limited therapies available. Prof. Atallah discusses strategies for optimizing use of current treatments and how the histone deacetylase (HDAC) inhibitor, pracinostat might fit into the treatment pathway.
Promising results from pracinostat in the Phase II Study
Prof. Atallah updates us on the interim results from the Phase II study of pracinostat in combination with azacitidine in high- to very high- risk MDS patients (NCT03151304). Prof. Atallah summarises the key information in this video.
Planned interim analysis of the Phase II study evaluating the pracinostat-azacitidine combination in high-risk MDS patients
Michael Keng, MD, from the University of Virginia, Charlottesville, VA, gives an oral presentation based on his poster from the ASH 2018 meeting. Describing, in detail, the rationale, design, results and conclusions from the Phase II study.